Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanocrystalline Megestrol Acetate for Cachexia in ES-SCLC
NCT06909383Phase 2Not yet recruiting
- Sponsor
- Guangzhou Institute of Respiratory Health
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of megestrol in cancer anorexia-cachexia syndrome (CACS), sponsored by Guangzhou Institute of Respiratory Health. Primary endpoint: Proportion of subjects with a body weight increase of more than 5% relative to the baseline at 12 weeks. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
megestrol
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on NCT06909383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06909383.